TriSalus Life Sciences, Inc.
TLSI
$5.22
-$0.31-5.61%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 67.91% | 67.75% | 68.96% | 49.31% | 36.45% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 67.91% | 67.75% | 68.96% | 49.31% | 36.45% |
| Cost of Revenue | 22.19% | 3.49% | 14.59% | 15.42% | 92.47% |
| Gross Profit | 77.76% | 83.83% | 82.16% | 56.85% | 28.40% |
| SG&A Expenses | 42.63% | 57.30% | 67.39% | 60.66% | 49.01% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.45% | 37.64% | 50.61% | 49.07% | 48.88% |
| Operating Income | 4.86% | -26.92% | -44.44% | -48.99% | -53.58% |
| Income Before Tax | -20.04% | -3.05% | -34.75% | -25.41% | -46.17% |
| Income Tax Expenses | -42.86% | -21.43% | 325.00% | 0.00% | 366.67% |
| Earnings from Continuing Operations | -20.02% | -3.04% | -34.77% | -25.41% | -46.20% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -20.02% | -3.04% | -34.77% | -25.41% | -46.20% |
| EBIT | 4.86% | -26.92% | -44.44% | -48.99% | -53.58% |
| EBITDA | 5.27% | -26.99% | -44.36% | -49.35% | -54.72% |
| EPS Basic | 97.76% | 98.16% | 62.66% | 62.73% | -297.48% |
| Normalized Basic EPS | 97.46% | 97.02% | 61.97% | 61.84% | -260.46% |
| EPS Diluted | 97.76% | 98.16% | 62.66% | 62.73% | -297.48% |
| Normalized Diluted EPS | 97.46% | 97.02% | 61.97% | 61.84% | -260.46% |
| Average Basic Shares Outstanding | 221.86% | 384.45% | 106.86% | 117.02% | -11.46% |
| Average Diluted Shares Outstanding | 221.86% | 384.45% | 106.86% | 117.02% | -11.46% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
